Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O’day Sells 102,619 Shares of Company Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel O’Day sold 102,619 shares of Gilead Sciences stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total value of $17,974,744.04. Following the completion of the sale, the chief executive officer directly owned 551,683 shares of the company’s stock, valued at approximately $96,632,794.28. The trade was a 15.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Thursday, November 5th, Daniel O’Day sold 9,810 shares of Gilead Sciences stock. The stock was sold at an average price of $175.17, for a total value of $1,718,417.70.
• On Monday, November 2nd, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $169.74, for a total value of $2,546,100.00.
• On Friday, October 30th, Daniel O’Day sold 15,881 shares of Gilead Sciences stock. The shares were sold at an average price of $175.25, for a total value of $2,783,145.25.
• On Thursday, October 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The shares were sold at an average price of $147.90, for a total value of $2,218,500.00.
• On Tuesday, September 1st, Daniel O’Day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00.

Gilead Sciences Stock Performance

NASDAQ GILD traded down $0.68 during trading hours on Friday, hitting $166.89. The company’s stock had a trading volume of 5,817,414 shares, compared to its average volume of 6,855,866. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $176.58. The company’s 50 day simple moving average is $152.68 and its two-hundred day simple moving average is $140.73. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. The company has a market cap of $207.00 billion, a P/E ratio of -52.81 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.47 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -1.07 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s payout ratio is presently -103.80%.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Gilead Sciences in the 2nd quarter valued at about $15,393,785,000. State Street Corp increased its stake in Gilead Sciences by 2.3% during the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after acquiring an additional 1,357,967 shares during the last quarter. Amundi increased its stake in Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock worth $1,468,836,000 after acquiring an additional 1,018,976 shares during the last quarter. Legal & General Group Plc bought a new stake in Gilead Sciences during the second quarter worth approximately $1,316,606,000. Finally, Deutsche Bank AG purchased a new stake in Gilead Sciences during the second quarter valued at approximately $918,387,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GILD. Sanford C. Bernstein restated an “outperform” rating and issued a $175.00 target price on shares of Gilead Sciences in a report on Monday. Jefferies Financial Group set a $196.00 target price on shares of Gilead Sciences in a research note on Wednesday. Cantor Fitzgerald increased their price target on Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, October 30th. UBS Group raised their price target on Gilead Sciences from $175.00 to $195.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, Needham & Company LLC set a $175.00 price objective on Gilead Sciences in a research report on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $170.15.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.